USPTO Art Unit 1631 Prosecution Statistics

Art Unit Information

Art Unit: 1631
Group: 1630
Tech Center: 1600
Total Cases: 11,652
Last Active: July 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19259859HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOFJuly 2025February 2026Abandon710NoNo
19188828GENE EDITING OF CAR-T CELLS FOR THE TREATMENT OF T CELL MALIGNANCIES WITH CHIMERIC ANTIGEN RECEPTORSApril 2025November 2025Allow610YesNo
19170240METABOLICALLY OPTIMIZED CELL CULTUREApril 2025October 2025Allow600NoNo
19071148Viral Vectors For Treating Neurogenic Detrusor OveractivityMarch 2025October 2025Allow821YesNo
19053424CULTURE MEDIUM AND METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN MACROPHAGES AND USE THEREOFFebruary 2025May 2025Allow301YesNo
18948773PREPARATION METHOD OF MESENCHYMAL STEM CELL (MSC) AND APPLICATION THEREOF IN KNEE PRODUCTNovember 2024August 2025Abandon910NoNo
18945053COMPOSITIONS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACIDNovember 2024May 2025Allow610NoNo
18930467COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITHOctober 2024December 2025Abandon1311NoNo
18919740RECOMBINANT AAV VECTORS FOR TREATING NEURODEGENERATIVE DISORDERSOctober 2024February 2026Allow1621YesNo
18913090CRYOPRESERVATION SOLUTION AND USE THEREOF IN REDUCING ISCHEMIA-REPERFUSION INJURY (IRI) OF CELL, TISSUE, OR ORGANOctober 2024January 2026Abandon1521NoNo
18816096GENE EDITING OF CAR-T CELLS FOR THE TREATMENT OF T CELL MALIGNANCIES WITH CHIMERIC ANTIGEN RECEPTORSAugust 2024January 2026Allow1721YesNo
18751145OPTIMIZED CYP4V2 GENE AND APPLICATION THEREOFJune 2024January 2025Allow710YesNo
18745792COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDJune 2024February 2025Allow810YesNo
18740874GENERATION OF NEURONS BY REPROGRAMMING OF OLIGODENDROCYTES AND OLIGODENDROCYTE PRECURSOR CELLSJune 2024February 2026Allow2031YesNo
18736487CARDIOPULMONARY PROGENITOR EXOSOMES, PREPARATION METHOD AND APPLICATION THEREOFJune 2024December 2025Abandon1831NoNo
18672796Targeting Nrip1 to Alleviate Metabolic DiseaseMay 2024May 2025Allow1101YesNo
18671080METHODS AND COMPOSITIONS FOR INSERTION OF ANTIBODY CODING SEQUENCES INTO A SAFE HARBOR LOCUSMay 2024February 2026Abandon2111NoNo
18668297Cell Growth Promoter and Application thereofMay 2024October 2025Allow1731YesNo
18663564MICRO-ENGINEERED MODELS OF THE HUMAN EYE AND METHODS OF USEMay 2024August 2025Allow1501YesNo
18644762SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PRODUCTSApril 2024May 2025Allow1221YesNo
18629638PLATELET DIAGNOSTIC IMAGING AGENTSApril 2024May 2025Abandon1310NoNo
18627513Fractionating Extracellular Matrix to Modulate Bioactivity and the Host ResponseApril 2024December 2025Abandon2111NoNo
18616511Gene Therapy For Neurodegenerative DisordersMarch 2024March 2025Allow1110NoNo
18616811GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMSMarch 2024September 2025Allow1811YesNo
18585322METHOD FOR PRODUCING PLATELETSFebruary 2024April 2025Abandon1310NoNo
18436632HUMAN FIBROLAMELLAR HEPATOCELLULAR CARCINOMAS (hFL-HCCS)February 2024December 2025Abandon2201NoNo
18426287CHIMERIC ANTIGEN RECEPTOR T CELL AND CONSTRUCTION METHOD THEREOF, AND ANTITUMOR DRUGJanuary 2024November 2024Allow911YesNo
18424664METHOD FOR GENERATING T CELL LINEAGE POPULATIONS FROM STEM/PROGENITOR CELLSJanuary 2024February 2025Allow1311YesNo
18422961METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLSJanuary 2024October 2025Abandon2120NoYes
18423155METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLSJanuary 2024October 2025Abandon2120NoYes
18411991PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPYJanuary 2024February 2025Allow1320YesNo
18410043RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING BIETTI CRYSTALLINE DYSTROPHYJanuary 2024April 2025Allow1511YesNo
18410900PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPYJanuary 2024October 2024Allow920YesNo
18406232ENGINEERED CAS PROTEIN AND USE THEREOFJanuary 2024January 2025Allow1221YesNo
18404087VECTOR-MEDIATED IMMUNE TOLERANCE IN THE EYEJanuary 2024June 2025Abandon1710NoNo
18391831RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLSDecember 2023January 2025Abandon1320NoNo
18534884Viral Vectors For Treating Neurogenic Detrusor OveractivityDecember 2023October 2024Abandon1111NoNo
18518831GENE-MODIFYING ENDONUCLEASESNovember 2023May 2025Allow1711YesNo
18499655LIPOSOME COMPOSITIONS AND METHODS OF USE THEREOFNovember 2023March 2025Abandon1610NoNo
18547750METHOD FOR CONSTRUCTING HUMAN PLURIPOTENT STEM CELL-DERIVED LIVER ORGANOID HAVING ENHANCED DRUG METABOLIC POTENTIAL AND LIVER ORGANOID CONSTRUCTED BY SAME METHODOctober 2023September 2024Allow1310YesNo
18496845CRISPR-based DNA Repair-Inhibiting Intratumoral Cancer TherapyOctober 2023June 2025Abandon1901NoNo
18288332METHOD FOR ENRICHING CELLS OR CELL NUCLEIOctober 2023May 2025Abandon1821YesNo
18493663ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSIDOctober 2023August 2024Allow920YesNo
18488346Gene Therapy For Neurodegenerative DisordersOctober 2023April 2025Abandon1810NoNo
18480956METHOD OF PRODUCING CANCER STEM CELLSOctober 2023September 2025Abandon2421NoNo
18372833ANTIBODY-EVADING VIRUS VECTORSSeptember 2023March 2024Allow510NoNo
18372334RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORSSeptember 2023February 2024Allow510YesNo
18472112METHODS FOR TREATING MYELOID MALIGNANCIESSeptember 2023July 2025Abandon2120NoNo
18551165METHOD TO SELECTIVELY PERMEABILIZE AND/OR FRAGMENTIZE CELLSSeptember 2023June 2024Allow901NoNo
18464908METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATIONSeptember 2023November 2025Abandon2611NoNo
18333705DEVELOPMENT OF AMNION-LIKE TISSUE FROM HUMAN PLURIPOTENT STEM CELLSSeptember 2023December 2025Allow3021YesNo
18459692CARDIAC STEM CELLS FOR CARDIAC REPAIRSeptember 2023May 2024Allow820YesNo
18459685CARDIAC STEM CELLS FOR CARDIAC REPAIRSeptember 2023October 2024Allow1422YesNo
18240744CONTINUOUSLY BIOPRINTED MULTILAYER TISSUE STRUCTUREAugust 2023October 2025Allow2621NoNo
18452233CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)August 2023September 2025Abandon2501NoNo
18231692IMMUNISATION WITH LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENSAugust 2023October 2023Allow300YesNo
18231697METHOD OF MAKING LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENSAugust 2023November 2023Allow300NoNo
18231693LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENSAugust 2023October 2023Allow200NoNo
18359240Use Of Perfusion To Enhance Production Of Fed-batch Cell Culture In BioreactorsJuly 2023April 2025Abandon2101NoNo
18224131CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYJuly 2023October 2024Allow1520YesNo
18223164EXTRACELLULAR MATRIX SUBSTITUTE IN A CELLULAR MICROCOMPARTMENTJuly 2023February 2026Allow3110NoNo
18351930COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASEJuly 2023March 2025Abandon2001NoNo
18348929MICROBIOME MODULATION OF A HOST BY DELIVERY OF DNA PAYLOADS WITH MINIMIZED SPREADJuly 2023May 2024Allow1001YesNo
18345366MINIGENE THERAPYJune 2023July 2025Allow2411NoNo
18345212BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOFJune 2023March 2025Abandon2101NoNo
18213593METHOD FOR PROMOTING AND IMPROVING PROPERTIES OF ADIPOSE TISSUE, TISSUE AND CELLS OBTAINED BY SAID METHODJune 2023March 2025Abandon2001NoNo
18333467EFFECTOR PROTEINS AND METHODS OF USEJune 2023November 2023Allow511YesNo
18331853DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLSJune 2023December 2025Allow3121YesNo
18256530CELL LINES FOR PRODUCTION OF ADENO-ASSOCIATED VIRUSJune 2023February 2026Allow3210NoNo
18330020Protection of Beta Cells from Immune AttackJune 2023October 2025Allow2820NoNo
18329455STROMAL STEM CELLSJune 2023December 2023Allow620NoNo
18329435STROMAL STEM CELLSJune 2023November 2023Allow510YesNo
18329469STROMAL STEM CELLSJune 2023December 2023Allow610YesNo
18325648METHODS OF TREATING CANCERMay 2023February 2026Allow3310NoNo
18038190METHODS AND COMPOSITIONS FOR LINKING RNA STEM LOOPSMay 2023October 2025Allow2900NoNo
18142133COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMSMay 2023October 2024Abandon1810YesNo
18309047METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTUREApril 2023December 2024Abandon2011NoNo
18140326TAIL-CONJUGATED RNASApril 2023May 2024Allow1221YesNo
18307256COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSIONApril 2023February 2026Allow3311YesNo
18304964SIGNALING NUMBER OF SUBBLOCK MERGE CANDIDATES IN VIDEO CODINGApril 2023January 2024Allow910NoNo
18250158ANTI-APOPTOTIC VECTOR AND METHOD OF USING THE SAMEApril 2023February 2026Allow3410NoNo
18301864MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN CANINES AND IMPROVED CELL CULTIVATION METHODSApril 2023January 2025Allow2131YesNo
18301856MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN EQUINES AND IMPROVED CELL CULTIVATION METHODSApril 2023January 2025Allow2121YesNo
18301228CONJUGATE SYSTEMS AND METHODS OF USE THEREOFApril 2023November 2025Allow3100NoNo
18296579RNA-Guided Human Genome EngineeringApril 2023April 2024Allow1220YesNo
18030683RECOMBINANT ADENO-ASSOCIATED VIRUSES FOR CNS OR MUSCLE DELIVERYApril 2023October 2025Allow3100YesNo
18295139LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023November 2023Abandon810NoNo
18129398Post-Natal Transplantation Of Factor VIII-Expressing Cells For Treatment of HemophiliaMarch 2023January 2026Allow3420YesNo
18194313LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTIONMarch 2023February 2025Abandon2210NoNo
18194551METHOD OF GENERATING MULTIPOTENT STEM CELLSMarch 2023December 2025Allow3310NoNo
18192682GRAFT SCAFFOLD FOR CARTILAGE REPAIR AND PROCESS FOR MAKING SAMEMarch 2023April 2025Abandon2510NoNo
18029158COMPOSITIONS AND METHODS FOR CD30 GENE MODIFICATIONMarch 2023March 2026Abandon3601NoNo
18190561ADENO-ASSOCIATED VIRUS COMPLEX WITH IMPROVED EXPRESSION OF RUNX3 GENE AND USES FOR PREVENTING OR TREATING KRAS MUTATED LUNG CANCERMarch 2023July 2023Allow410NoNo
18190630MODIFIED COMPLEX PLATFORM OF ADENO-ASSOCIATED VIRUS WITH IMPROVED RATE OF EXPRESSION OF LOADED GENES AND REDUCED GENOTOXICITYMarch 2023December 2023Allow820NoNo
18190783BONE MARROW DERIVED NEUROKININ-1 RECEPTOR POSITIVE (NK1R+) MESENCHYMAL STEM CELLS FOR THERAPEUTIC APPLICATIONSMarch 2023October 2025Abandon3111NoNo
18190590NUCLEIC ACID MOLECULE COMPRISING ASYMMETRICALLY MODIFIED ITR FOR IMPROVING EXPRESSION RATE OF INSERTED GENE, AND USE THEREOFMarch 2023December 2023Allow920YesNo
18188312TRIFUNCTIONAL T CELL-ANTIGEN COUPLER AND METHODS AND USES THEREOFMarch 2023September 2024Abandon1821NoNo
18123920METHODS FOR THE TREATMENT OF BETA-THALASSEMIAMarch 2023March 2025Abandon2310NoNo
18184184Compositions and Methods of TreatmentMarch 2023January 2026Allow3410NoNo
18180791VIRAL VECTORS FOR CANCER THERAPYMarch 2023December 2023Allow1020YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1631.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
510
Examiner Affirmed
352
(69.0%)
Examiner Reversed
158
(31.0%)
Reversal Percentile
43.8%
Lower than average

What This Means

With a 31.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1687
Allowed After Appeal Filing
308
(18.3%)
Not Allowed After Appeal Filing
1379
(81.7%)
Filing Benefit Percentile
3.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1631 - Prosecution Statistics Summary

Executive Summary

Art Unit 1631 is part of Group 1630 in Technology Center 1600. This art unit has examined 11,652 patent applications in our dataset, with an overall allowance rate of 39.0%. Applications typically reach final disposition in approximately 45 months.

Comparative Analysis

Art Unit 1631's allowance rate of 39.0% places it in the 2% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1631 receive an average of 2.47 office actions before reaching final disposition (in the 86% percentile). The median prosecution time is 45 months (in the 5% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.